Resolvin E1は骨芽細胞におけるIL-17誘導性RANKL発現とRANKL誘導性破骨細胞分化を抑制することで破骨細胞形成および骨吸収を抑制する by Funaki, Yoshihiro
8Yonago Acta Medica 2018;61:008–018   Original Article
Corresponding author: Yasuyuki Hasegawa, MD, PhD
hasechi@med.tottori-u.ac.jp
Received 2017 November 27
Accepted 2017 December 21 
Abbreviations: BLT1, leukotriene B4 receptor subtype 1; COX, cy-
clooxygenase; EPA, eicosapentaenoic acid; ELISA, enzyme-linked 
immunosorbent assay; DHA, docosahexaenoic acid; FBS, fetal bo-
vine serum; IL, interleukin; mPGES-1, microsomal prostaglandin E 
synthase-1; MMP, matrix metalloproteinase; NFATc1, nuclear factor 
of activated T cells c1; OPG, osteoprotegerin; PBS, phosphate-buff-
ered saline; PGE2, prostaglandin E2; PUFA, polyunsaturated fatty 
acid; RANKL, receptor activator of nuclear factor-κB ligand; RvE1, 
resolvin E1; TNF, tumor necrosis factor; TRAP, tartrate-resistant 
acid phosphatase
Resolvin E1 Inhibits Osteoclastogenesis and Bone Resorption by Suppressing  
IL-17-induced RANKL Expression in Osteoblasts and RANKL-induced Osteoclast 
Differentiation
Yoshihiro Funaki, Yasuyuki Hasegawa, Ryota Okazaki, Akira Yamasaki, Yuriko Sueda, Akihiro Yamamoto, 
Masaaki Yanai, Takehito Fukushima, Tomoya Harada, Haruhiko Makino and Eiji Shimizu
Division of Medical Oncology and Molecular Respirology, Department of Multidisciplinary Internal Medicine, School of Medicine, 
Tottori University Faculty of Medicine, Yonago 683-8504, Japan
ABSTRACT 
Background    Resolvin E1 (RvE1) derived from the 
ω-3 polyunsaturated fatty acid eicosapentaenoic acid is 
known to be a potent pro-resolving lipid mediator that 
prevents chronic inflammation and osteoclastogenesis. 
We investigated the inhibitory effects of RvE1 on osteo-
clastogenesis and bone resorption to clarify its therapeu-
tic potential for rheumatoid arthritis (RA).
Methods    Receptor activator of nuclear factor-κB li-
gand (RANKL)-induced osteoclast differentiation was 
assessed with tartrate-resistant acid phosphatase stain-
ing. RANKL-induced bone resorption was assessed 
by the measurement of pit formation using calcium 
phosphate-labeled fluorescent polyanionic molecules in 
RAW264.7 cells as osteoclast precursors. The effects of 
RvE1 on the RANKL-induced mRNA expression of os-
teoclast-specific genes and transcriptional factors such as 
c-fos and nuclear factor of activated T cells c1 (NFATc1) 
in RAW264.7 cells were measured by quantitative re-
al-time PCR. The distribution of NFATc1 induced by 
RANKL was evaluated by immunofluorescence stain-
ing in RAW264.7 cells. To analyze the mechanism of 
the inhibitory effect of RvE1 on osteoclastogenesis, we 
measured IL-17-induced RANKL mRNA expression 
in MC3T3-E1 osteoblast cells treated with RvE1 using 
quantitative real-time PCR and determined the level of 
prostaglandin E2 (PGE2) production by enzyme-linked 
immunosorbent assay.
Results    RvE1 significantly suppressed RANKL-in-
duced osteoclast differentiation and bone resorption. 
RvE1 inhibited the RANKL-induced mRNA expression 
of osteoclast-specific genes along with the transcription 
factors NFATc1 and c-fos. Moreover, NFATc1 translo-
cation from the cytoplasm to the nucleus of RAW264.7 
cells was suppressed following RvE1 treatment. RvE1 
also inhibited IL-17-induced RANKL mRNA expres-
sion and PGE2 production in MC3T3-E1 cells.
Conclusion    RvE1 inhibited osteoclastogenesis and 
bone resorption by suppressing RANKL-induced 
NFATc1 and c-fos expression in osteoclasts and IL-17-
induced RANKL expression through the autocrine ac-
tion of PGE2 in osteoblasts. Our data suggest RvE1 as a 
new therapeutic target of RA.
Key words    interleukin-17; osteoblasts; osteoclasts; 
RANK ligand; resolvin E1
The bone undergoes continuous remodeling to achieve 
a balance between bone formation and resorption medi-
ated by osteoblasts and osteoclasts, respectively. Rheu-
matoid arthritis (RA) is a chronic inflammatory auto-
immune disease characterized by progressive synovial 
inflammation and destruction of the joint cartilage and 
bone.1 In particular, RA involves a breakdown of met-
abolic balance in the bone, and is characterized by an 
increase in bone resorption that results in impaired bone 
formation.2 This imbalance is caused by the increase 
of various inflammatory cytokines, including receptor 
activator of nuclear factor-κB ligand (RANKL) and 
its competitive inhibitor osteoprotegerin (OPG), in the 
inflammatory tissue.3, 4 Thus, anti-inflammatory drugs 
are most commonly prescribed to treat the symptoms of 
RA. However, recent evidence points to the beneficial 
effects of natural compounds on reducing inflammatory 
cascades, providing new options for RA treatment.
 For example, a diet enriched in ω-3 polyunsaturated 
fatty acids (PUFAs) was found to reduce joint stiffness 
in the morning and the number of tender joints,5 and 
also decreased the levels of inflammatory cytokines in 
the blood, including tumor necrosis factor-alpha (TNF-α), 
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interleukin (IL)-1β, and IL-6.6, 7 Indeed, several random-
ized clinical studies have revealed that dietary supple-
mentation with ω-3 PUFAs is efficacious in reducing 
joint pain, the duration of morning stiffness, the number 
of tender or swollen joints and non-steroidal anti-in-
flammatory drug usage in RA patients.8, 9 However, the 
mechanisms of these clinical effects of ω-3 PUFAs have 
remained unclear. Recent discoveries demonstrate that 
ω-3 PUFAs such as eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) can be enzymatically con-
verted in vivo to novel bioactive lipid mediators termed 
specialized pro-resolving mediators, including resolvins, 
protectins and maresins, which promote the resolution 
of inflammation and have more potent effects than their 
lipid precursors.10
 One of the specialized pro-resolving mediators 
derived from EPA, resolvin E1 (5S, 12R, 18R-trihy-
droxy-6Z, 8E, 10E, 14Z, 16E-eicosapentaenoic acid; 
RvE1), was originally identified in exudates of the mu-
rine dorsal air pouch, an acute inflammation model.11 
Recent findings demonstrated that RvE1 had protective 
effects in periodontal disease,12 peritonitis,13 asthmatic 
airway inflammation,14 bacterial pneumonia and acute 
lung injury in vivo.15 Accordingly, we speculated that the 
same bone-protective effects noted in periodontal dis-
ease might be applicable to RA. There have been only a 
few reports on the regulation of RvE1 for bone resorp-
tion and osteoclast differentiation,16 and the effects and 
mechanism of RvE1 on bone remodeling are still not 
fully understood. Therefore, in this study, we originally 
investigated the effects of RvE1 on the inflammation 
and signaling pathways in osteoclasts and osteoblasts to 
provide a foundation for RvE1 as a new therapeutic ap-
proach in RA treatment. Our results are the first to indi-
cate that RvE1 interacts with osteoclasts and osteoblasts 
via inhibition of RANKL production in osteoblasts.
 RANKL is a member of the TNF superfamily of cy-
tokines and is known to induce osteoclastogenesis from 
monocytes or macrophages. The binding of RANKL to 
its receptor RANK, expressed on osteoclast precursors, 
induces the expression and/or activation of transcription 
factors, including nuclear factor of activated T cells c1 
(NFATc1) and c-fos, which have been shown to be es-
sential for osteoclast differentiation.17, 18 
 Pro-inflammatory molecules play a significant, but 
primarily indirect, role in osteoclast regulation as they 
act through modulating RANKL and OPG.19 TNFα, 
IL-1, IL-6, IL-11 and IL-17 act on osteoblasts and 
bone marrow stromal cells to increase RANKL and/
or decrease OPG expression in osteoblasts.20, 21 IL-17 is 
a pro-inflammatory cytokine induced by a subset of T 
helper 17 cells.3, 22 In osteoblasts, RANKL is induced 
by prostaglandin E2 (PGE2), which is in turn strongly 
induced by IL-17; however, this PGE2-induced upregula-
tion of RANKL expression could be inhibited by NS398, 
a selective cyclooxygenase-2 (COX-2) inhibitor.3, 23 Thus, 
IL-17 indirectly induces osteoclastogenesis via PGE2-in-
duced RANKL expression in osteoblasts and has been 
implicated in the promotion of the pathogenesis of RA. 
Based on this background, in this study, we focused 
on the potential effects of RvE1 on mediating IL-17-
induced osteoclastogenesis to alleviate the inflammation 
associated with RA. We further examined the potential 
mechanism underlying the effects of RANKL, IL-17 
and/or RvE1 in RAW264.7 and mouse MC3T3-E1 cells 
as osteoclasts and osteoblasts, respectively. We exam-
ined the effect on osteoclastogenesis by determining the 
expression of matrix metalloproteinase-9 (MMP-9) and 
cathepsin K, which are highly expressed in osteoclastic 
cells and considered as markers of mature osteoclasts 
that play important roles in osteolysis.24 PGE2 produc-
tion tends to be induced by endogenous COX-2 and 
microsomal PGE synthase-1 (mPGES-1). Therefore, 
the COX-2 and mPGES-1 mRNA expression levels 
were examined with real-time PCR, and the production 
level of PGE2 was examined with an enzyme-linked 
immunosorbent assay (ELISA) in MC3T3-E1 cells to 
understand the mechanism of the inhibitory effects of 
RvE1 on osteoclastogenesis. Osteoblasts are involved 
in osteoclast regulation by expressing RANKL on their 
membranes or releasing it as a soluble factor.2 We there-
fore further verified the mRNA expression of RANKL 
and its competitive inhibitor OPG in MC3T3-E1 cells by 
real-time PCR. Together, these in vitro results could pro-
vide a foundation for the clinical application of RvE1 in 
maintaining the balance of bone metabolism and in the 
treatment or prevention of RA. 
MATERIALS AND METHODS
Cell culture and reagents
RAW264.7 cells were purchased from American Type 
Culture Collection (Manassas, VA) and were used as 
osteoclastic cells. Mouse calvarial cells (MC3T3-E1) 
were purchased from the RIKEN BioResource Center 
(Tsukuba, Japan) and were used as osteoblastic cells. 
RAW264.7 cells were cultured in Dulbecco’s minimal 
essential medium (D-MEM; Wako Pure Chemicals, 
Osaka, Japan) containing 10% fetal bovine serum 
(FBS), 100 µg/mL penicillin and 100 µg/mL streptomy-
cin. MC3T3-E1 cells were cultured in α-MEM (Wako 
Pure Chemicals) containing 10% FBS, 100 µg/mL 
penicillin and 100 µg/mL streptomycin. Both cell lines 
were cultured at 37 °C in a humidified 5% CO2 atmo-
sphere. RAW264.7 cells were cultured with or without 
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soluble RANKL (Oriental Yeast, Tokyo, Japan) and 
RvE1 (Toronto Research Chemicals, Toronto, Canada). 
MC3T3-E1 cells were cultured with or without IL-17 
(Pepro Tech, Rocky Hill, NJ) and RvE1.
Cell proliferation assay
Cell viability was assessed using Cell Counting Kit-8 
(CCK-8; Dojindo, Kumamoto, Japan). RAW264.7 and 
MC3T3-E1 cells were seeded in 96-well plates at 5.0 × 
103 cells/well in D-MEM or MEM-α each containing 
10% FBS. Following incubation for 24 h, the cells were 
treated with 0, 50, 100 or 200 nM RvE1. After 1 h, the 
cells were treated with 100 ng/mL RANKL (RAW 
264.7 cells) or 50 ng/mL IL-17 (MC3T3-E1 cells). After 
24 h, 10 µL CCK-8 solution was added to the culture 
and the cells were further incubated in the dark at 37 °C 
for 2 h. The plate was then read using a Sunrise micro-
plate analyzer (Tecan, Mannedorf, Switzerland) at 450 
nm with a reference at 600 nm. The number of surviving 
cells was quantifi ed by measuring the absorbance at this 
wavelength.
 
Tartrate-resistant acid phosphatase (TRAP) stain-
ing
RAW264.7 cells were plated in 24-well microplates at a 
density of 1.0 × 104 cells/mL and left overnight to settle. 
Conditioned medium containing 50 or 100 ng/mL sol-
uble RANKL was then added to the cells and cultured 
for 6 days. On day 7 of culture, the cells were fi xed and 
stained using a TRAP staining kit (Wako Pure Chemi-
cals) according to the manufacturer’s instructions. The 
number of osteoclast-like cells per well was then count-
ed (TRAP-positive cells with more than three nuclei). 
Each experiment was performed in duplicate.
Quantitative real-time PCR
Total RNA was isolated from cultured 
cells using the RNeasy Plus mini kit 
(Qiagen, Valencia, CA) according to 
the manufacturer’s instructions. The 
mRNA was reverse-transcribed into 
cDNA using the Super Script VILO 
Master Mix (Invitrogen, Carlsbad, CA) 
and the resultant cDNA was subjected 
to real-time PCR using the TaqMan 
Fast Advanced Master Mix (Applied 
Biosystems, Carlsbad, CA). Specific 
primers (Table 1) were purchased from 
Applied Biosystems (Foster City, CA). 
PCR was performed using the TaKa-
Ra PCR Thermal Cycler Dice system 
(Takara Bio, Kusatsu, Japan) under the 
following conditions: initial holding at 
25 °C for 10 min and then 42.0 °C for 60 min and fi nally 
85.0 °C for 5 min. Real-time PCR was performed on a 
ViiA7 Real-Time PCR system (Applied Biosystems) for 
40 cycles of 95 °C for 1 s and 60 °C for 20 s. The ex-
pression levels of NFATc1, c-fos, cathepsin K, MMP-9, 
RANKL, OPG, COX-2 and mPGES-1 were normalized 
to that of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). All real-time PCR experiments were per-
formed in triplicated and analyzed by the comparative 
2-∆∆Ct relative quantifi cation meth od.
Immunoﬂ uorescence staining
RAW264.7 cells were cultured in glass chamber slides 
(Lab-Tek II Chamber Slide w/Cover RS Glass Slide 
Sterile; Nalge Nunc) for 24 h with or without RANKL 
plus RvE1. The glass chamber slides were then removed, 
washed in phosphate-buffered saline (PBS), fi xed with 
4% paraformaldehyde for 20 min, permeabilized with 
0.5% TritonX-100 for 1 h, incubated with bovine serum 
albumin for 1 h to block non-specifi c binding and then 
incubated with mouse NFATc1 monoclonal antibody (di-
luted 1:50; Santa Cruz Biotechnology, Dallas, TX) over-
night at 4 °C. The cells were washed again in PBS and 
incubated with Alexa Fluor 488 goat anti-mouse second-
ary antibody (diluted l:2000; Life Technologies, Carls-
bad, CA) for 1 h. The nuclei of cells were stained using 
the blue fluorescent dye 4’,6-diamidino-2-phenylindole 
in Vectashield mounting medium (Vector Laboratories, 
Burlingame, CA). Images were obtained with a confo-
cal microscope (TCS-SP2 confocal microscope; Leica, 
Wetzlar, Germany). 
Bone resorption assay
The bone resorption assay was performed using Bone 
Table 1. Primers for real-time PCR
Genes Assay IDa RefSeq Exon Boundary
Product 
length (bp)
NFATc1 Mm00479445_m1 NM_00116409.1 7-8 75
c-fos Mm00487425_m1 NM_010234.2 1-2 59
Cathepsin K Mm00484039_m1 NM_007802.4 7-8 73
MMP-9 Mm00442991_m1 NM_013599.3 5-6 80
RANKL Mm00441906_m1 NM_011613.3 2-3 66
OPG Mm00435454_m1 NM_008764.3 4-5 71
COX-2 Mm00478374_m1 NM_011198.3 5-6 80
mPGES-1 Mm00452105_m1 NM_022415.3 2-3 87
GAPDH Mm99999915_m1 NM_001289726.1 2-3 107
COX-2, Cyclooxygenase-2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 
MMP-9, matrix metalloproteinase-9; mPGES-1, microsomal prostaglandin E synthe-
tase-1; NFATc1, nuclear factor of activated T cells c1; OPG, osteoprotegerin; RANKL, 
receptor activator of nuclear factor κB ligand. a: TaqMan Gene Expression Assay 
(Applied Biosystems)
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Resorption Assay Kit 24 (PG Research, Kodaira, Ja-
pan).25 First, 0.5 mL fluorescein amine-labeled chon-
droitin polysulfate (Bone Resorption Assay FACS) was 
added to each well of a calcium phosphate-coated 24-
well plate (Bone Resorption Assay 24) and incubated at 
37 °C in a humidifi ed 5% CO2 atmosphere for 2 h under 
a light-shielded condition. After the incubation, each 
well of the 24-well plate was washed with 1 mL PBS 
twice and then 1 mL MEM-α without phenol red (Wako 
Pure Chemicals) containing 10% FBS was added. The 
RAW264.7 cells were inoculated into each well at a 
density of 1.0 × 104 cells/mL and allowed to attach for 4 
h befo re being treated with 50 or 100 nM RvE1 for 1 h, 
followed by incubation with 10–200 ng/mL RANKL for 
6 days without a medium change. RvE1 and RANKL 
were added at the same dose after 3 days. After 6 days, 
100 µL of the culture supernatant from each well was 
harvested into a 96-well plate and mixed with 50 µL of 
0.1 N NaOH (Bone Resorption Assay Buffer). The fl u-
orescence intensity of the culture supernatant was mea-
sured using a fluorescence plate reader (Infinite F500, 
Tecan, Mannedorf, Switzerland) with an excitation 
wavelength of 485 nm and emission wavelength of 535 
nm. The remaining plates were washed with PBS and 
treated with 5% sodium hypochlorite for 5 min. After 
washing the plates with water and drying them, the pit 
area was photographed by a fluorescence microscope 
(BZ-8100, Keyence, Osaka, Japan).
ELISA 
The amount of PGE2 in the culture medium was deter-
mined using a commercially available ELISA kit (Enzo 
Life sciences, Farmingdale, NY) according to the man-
ufacturer’s instructions, and the data were converted 
to pg/mL. Finally, duplicate assays were performed on 
each sample, and the absorbance at 405 nm was record-
ed.
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Fig. 1. Effects of RvE1 on the number of TRAP-positive osteo-
clast-like RAW264.7 cells.
RAW264.7 cells were cultured in conditioned medium contain-
ing 50 or 100 ng/mL RANKL with or without 100 nM RvE1 for 
6 days. Osteoclast-like cells were stained by TRAP on day 7 of 
culture. Representative microscope images are shown. Original 
magnifi cation, × 100 (A). The number of TRAP-positive multi-
nucleated cells in the conditioned medium treated with 100 nM 
RvE1 was signifi cantly reduced compared to groups treated with 
both 50 and 100 ng/mL RANKL (B). Data are expressed as the 
mean ± SD (n = 3). **P < 0.01 versus RvE1 (–) in the presence of 
50 or 100 ng/mL RANKL. MNC, multinucleated cell; RANKL, 
receptor activator of nuclear factor-κB ligand; RvE1, resolvin E1; 
TRAP, tartrate-resistant acid phosphatase.
(A)
(B)
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Fig. 2. Effects of RvE1 on osteoclastic bone resorption in 
RAW264.7 cells. RAW264.7 cells were cultured with 50 or 100 
nM RvE1 in the presence of different doses (10, 100, 200 ng/mL) 
of RANKL for 6 days. Resorption pits were observed on day 
7 in the conditioned medium treated with 10 ng/mL RANKL, 
whereas no resorption pit was observed in the medium without 
RANKL. However, the area of resorption pits was decreased by 
treatment with 100 nM RvE1. Original magnifi cation, × 200 (A). 
The levels of fl uorescence intensity, representing the activity of 
osteoclast generation, of the supernatant in the presence of 10, 
100 and 200 ng/mL RANKL were determined (B). The levels 
of fluorescence intensity of the supernatant treated with 50 or 
100 nM RvE1 in the presence of 10 ng/mL RANKL were deter-
mined (C). Data are expressed as the mean ± SD (n = 3). *P < 0.05, 
**P < 0.01 versus control (B). **P < 0.01 versus RANKL (C). 
RANKL, receptor activator of nuclear factor-κB ligand; RvE1, 
resolvin E1.
Statistical analysis 
The experimental data were analyzed using Graphpad 
Prism 6 (Graphpad Software, San Diego, CA). All ex-
periments were conducted separately at least three times, 
and all data are presented as the mean ± SD. Statistical-
ly significant differences were assessed by analysis of 
variance (followed by Bonferroni multiple comparisons 
test) or Student’s t-test with P-values < 0.05 considered 
signifi cant.
RESULTS 
RvE1 reduced the number of TRAP-positive osteo-
clast-like RAW264.7 cells
The CCK-8 assay confi rmed that any effects of RvE1 on 
osteoclastogenesis would not be due to the cytotoxicity 
of this compound, since no change in cell viability was 
noted in RAW264.7 cells and MC3T3-E1 cells treated 
with RvE1 (data not shown).
 TRAP-positive osteoclast-like cells were observed 
when RAW264.7 cells were cultured in the presence 
RANKL, and the number of positive cells increased 
in a dose-dependent manner. However, the number of 
TRAP-positive cells decreased in the conditioned medi-
um treated with both 100 nM RvE1 and RANKL (Fig. 
1A), representing a statistically significant reduction 
compared to those detected with 50 and 100 ng/mL 
RANKL alone (Fig. 1B).
RvE1 suppressed osteoclastic bone resorption in 
RAW264.7 cells
To assess the effects of RvE1 on bone resorption, 
RAW264.7 cells were cultured with or without RvE1 in 
the presence of different doses (10, 100 and 200 ng/mL) 
of RANKL. Resorption pits were observed in the con-
ditioned medium of RAW264.7 cells treated with 10 ng/
mL RANKL, which were not detected in the medium 
without RANKL (Fig. 2A). The fl uorescence intensity, 
representing the activity of osteoclast generation, sig-
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Fig. 3. Effects of RvE1 on RANKL-in-
duced NFATc1 and c-fos mRNA 
expression, and NFATc1 translocation 
in RAW264.7 cells. RAW264.7 cells 
were pretreated with RvE1 and then 
stimulated with 100 ng/mL RANKL 
for 24 or 48 h, and the expression lev-
els of NFATc1 and c-fos mRNA were 
determined by real-time PCR (A and 
B). The expression levels of mPGES-1 
and COX-2 mRNA in the presence or 
absence of 100 ng/mL RANKL and/or 
100 nM RvE1 at 48 h were determined 
by real-time PCR (C and D). Data are 
expressed as the mean ± SD (n = 3). 
**P < 0.01, ***P < 0.001 versus 0 h (A 
and B). *P < 0.05 versus RANKL (C 
and D). RAW264.7 cells were exposed 
to 50 or 100 ng/mL RANKL with or 
without 100 nM RvE1 for 48 h. The 
location of NFATc1 (green) was iden-
tified with an immunofluorescence 
assay. 4’,6-diamidino-2-phenylindole 
(DAPI) was used to label the nuclei 
(blue). Scale bar = 20 µm (E). DAPI, 
4’,6-diamidino-2-phenylindole; GAP-
DH, glyceraldehyde-3-phosphate dehy-
drogenase; NFATc1, nuclear factor of 
activated T cells c1; RANKL, receptor 
activator of nuclear factor-κB ligand; 
RvE1, resolvin E1.
Fig.	  3	
NFATc1	 DAPI	 Merge	
Control	
RANKL	  50	  ng/mL	
RANKL	  50	  ng/mL	  
+	  RvE1　100	  nM	
(E)	
(E)
14
Y. Funaki et al.
Fig.	  4	
1500	
500	
0	
Fo
ld
	  c
ha
ng
e	  
(M
M
P9
/G
A
PD
H
)	
1000	
**	
(A)	  
**	
0	 24	 48	
	  RANKL	  (100	  ng/mL)	
Time	  (h)	 72	
Fig.	  4	
(B)	
150	
50	
0	
Fo
ld
	  c
ha
ng
e	  
(C
at
he
ps
in
	  K
/G
A
PD
H
)	
100	
**	
*	
0	 24	 48	
	  RANKL	  (100	  ng/mL)	
Time	  (h)	 72	
Fig.	  4	
**	
0	
100	
200	
300	
400	
Fo
ld
	  c
ha
ng
e	  
(M
M
P9
/G
A
PD
H
)	
RANKL	  
(100	  ng/mL)	
50	
**	
(C)	
*	
RvE1	  
(nM)	
–	 +	 +	 +	 +	
100	 200	0	0	
Fig.	  5	
(A)	
Fo
ld
	  c
ha
ng
e	  
(R
A
N
KL
/G
A
PD
H
)	
0	
1	
2	
3	
4	
***	*	
*	
1	 10	 50	
IL-­‐17	  
(ng/mL)	
0	
Fig.	  4	
(D)	
*	
0	
5	
10	
15	
Fo
ld
	  c
ha
ng
e	  
(C
at
he
ps
in
	  K
/G
A
PD
H
)	
**	
RANKL	  
(100	  ng/mL)	
50	RvE1	  
(nM)	
–	 +	 +	 +	 +	
100	 200	0	0	
Fig.	  5	
(B)	
Fo
ld
	  c
ha
ng
e	  
(R
A
N
KL
/G
A
PD
H
)	
0.0	
0.5	
1.0	
1.5	
*	
IL-­‐17	  
(50	  ng/mL)	
RvE1	  
(nM)	
–	 +	 +	 +	
100	 200	0	0	
(A)
(C)
(A)
(B)
(D)
(B)
Fig. 4. Effects of RvE1 on RANKL-induced MMP-9 and cathepsin K mRNA expression in RAW264.7 cells.RAW264.7 cells were pre-
treated with RvE1 and then stimulated with 100 ng/mL RANKL for 24 or 48 h, and the mRNA expression levels of MMP-9 and cathep-
sin K were determined by real-time PCR (A and B). The mRNA expression levels of MMP-9 and cathepsin K in the presence or absence 
of 100 ng/mL RANKL and/or 100 nM RvE1 at 48 h were determined by real-time PCR (C and D). Data are expressed as the mean ± SD (n 
= 3), *P < 0.05, **P < 0.01 versus 0 h (A and B). *P < 0.05, **P < 0.01 versus RANKL (C and D). GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase; MMP-9, matrix metalloproteinase-9; RANKL, receptor activator of nuclear factor-κB ligand; RvE1, resolvin E1.
Fig. 5. Effect of RvE1 on IL-17-induced RANKL mRNA expression in MC3T3-E1 cells. MC3T3-E1 cells were cultured in the presence 
of 1, 10 and 50 ng/mL IL-17, and the mRNA expression level of RANKL was determined by real-time PCR (A). The cells were also 
cultured with 50, 100 and 200 nM RvE1 in the presence of 50 ng/mL IL-17. The expression levels of RANKL mRNA in the presence or 
absence of 50 ng/mL IL-17 and/or 100 nM RvE1 at 24 h were determined by real-time PCR. The value of the fold change in mRNA lev-
els of IL-17 alone was normalized as 1. (B). Data are expressed as the mean ± SD (n = 3), *P < 0.05, ***P < 0.01 versus control (A). *P < 
0.05 versus IL-17 alone (B). GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IL, interleukin; RANKL, receptor activator of nuclear 
factor-κB ligand; RvE1, resolvin E1.
15
RvE1 inhibits osteoclastogenesis and bone resorption
nifi cantly increased compared to that of the control in 
a RANKL concentration-dependent manner (Fig. 2B). 
However, co-treatment with 100 nM RvE1 decreased 
the area of the resorption Pits (Fig. 2A) and signifi cantly 
reduced the fl uorescent intensity compared to that of the 
vehicle control (Fig. 2C). 
RvE1 suppressed RANKL-induced NFATc1 and 
c-fos mRNA expression and NFATc1 nuclear trans-
location in RAW264.7 cells
The NFATc1 and c-fos mRNA levels of RAW264.7 cells 
treated with 100 ng/mL RANKL increased in a time-de-
pendent manner with a signifi cant increase at 48 h, and 
at both 24 and 48 h, respectively, compared to 0 h (Figs. 
3A and B). However, co-treatment with 100 nM RvE1 
signifi cantly reduced the RANKL-induced NFATc1 and 
c-fos mRNA expression levels compared to those of the 
vehicle control (Figs. 3C and D). The immunofluores-
cence assay showed that NFATc1 was mainly localized 
in the cytoplasm in the control cells, but was distinctly 
translocated to the nucleus after treatment with 50 ng/
mL RANKL for 48 h; however, the nuclear immunos-
taining intensity was reduced in the presence of 100 nM 
RvE1 (Fig. 3E). 
RvE1 reduced RANKL-induced MMP-9 and 
cathepsin K mRNA expression in RAW264.7 cells
The mRNA expression levels of MMP-9 and cathepsin 
K signifi cantly increased at 48 and 72 h in RAW264.7 
cells treated with 100 ng/mL RANKL compared 
to 0 h (Figs. 4A and B). RvE1 significantly reduced 
RANKL-induced MMP-9 and cathepsin K mRNA ex-
pression in a dose-dependent manner compared to the 
vehicle control (Figs. 4C and D). 
RvE1 reduced IL-17-induced RANKL mRNA ex-
pression in MC3T3-E1 cells
After culturing the cells with IL-17 (1, 10 or 50 ng/mL) 
for 24 h, the RANKL mRNA level was significantly 
increased in a dose-dependent manner (Fig. 5A). Pre-
treatment with RvE1 (100 or 200 nM) for 24 h tended 
to reduce the IL-17-induced RANKL mRNA level in a 
dose-dependent manner with signifi cant downregulation 
observed following treatment with 200 nM RvE1 (Fig. 
5B). Similarly, the OPG mRNA level was decreased 
after IL-17 treatment in a dose-dependent manner, and 
OPG expression was upregulated with RvE1 pretreat-
ment (data not shown). Therefore, RvE1 improved the 
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Fig. 6. Effects of RvE1 on IL-17-induced PGE2 production and 
mRNA expression of COX-2 and mPGES-1 in MC3T3-E1 
cells.MC3T3-E1 cells were cultured with 30 ng/mL IL-17 for 
24 h after pretreatment with 100 nM RvE1 and the PGE2 pro-
duction level was determined by ELISA. Data are expressed as 
the mean ± SD (n = 2 for control, n = 3 for 10 ng/mL IL-17 and 
IL-17 + 100 nM RvE1); P = 0.075 versus IL-17 (A). MC3T3-E1 
cells were cultured with or without 100 nM RvE1 in the pres-
ence of 30 ng/mL IL-17 for 24 h, and the mRNA expression 
levels of COX-2 (B) and mPGES-1 (C) were determined by 
real-time PCR. Data are expressed as the mean ± SD (n = 3 for 
COX-2, n = 5 for mPGES-1). *P < 0.05 versus IL-17. COX-2, 
cyclooxygenase-2; GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase; IL, interleukin; mPGES-1, microsomal prostaglan-
din E synthase-1; PGE2, prostaglandin E2; RvE1, resolvin E1.
16
Y. Funaki et al.
imbalance in the RANKL/OPG ratio, which is likely to 
induce an inhibitory effect on bone resorption.
RvE1 reduced IL-17-induced PGE2 production and 
the mRNA expression levels of COX-2 and mPG-
ES-1 in MC3T3-E1 cells
The ELISA results showed that pretreatment of 
MC3T3-E1 cells with RvE1 inhibited the stimulatory 
effect of IL-17 on PGE2 production; the PGE2 produc-
tion levels in the presence of 100 nM RvE1 tended to 
be reduced compared to those of cells treated with the 
vehicle control (Fig. 6A). RvE1 treatment also signifi-
cantly reduced the IL-17-induced expression of COX-2 
and mPGES-1 mRNA compared to the vehicle control 
group (Figs. 6B and C).
DISCUSSION
RvE1 is a member of the E series of resolvins that are 
biosynthesized from EPA.11 Recent reports identified an-
other member of the E series of resolvins, called resolvin 
E2 (RvE2) and resolvin E3 (RvE3).26, 27 Although Barden 
and colleagues28 showed that synovial fluid RvE2 was 
negatively associated with pain score in humans, the 
effects of RvE2 and RvE3 on osteoclasts and osteoblasts 
were not fully understood. Thus, we investigated RvE1 
as a therapeutic agent for RA. With respect to bone me-
tabolism, RvE1 was shown to inhibit osteoclast growth 
and bone resorption.16 Gao and colleagues29 reported that 
RvE1 has a direct bone-preserving function via chemo-
kine-like receptor 1, which mediates bone preservation 
in osteoblasts. Moreover, a recent study indicated that 
RvE1 influenced pain, a major symptom of RA, showing 
simultaneous anti-inflammatory and analgesic properties 
in experimental models closely related to translational 
sites in humans.30 These studies have demonstrated the 
good therapeutic potential of RvE1 in many chronic in-
flammatory diseases. Indeed, RvE1 (Rx-10001) and its 
synthetic analog (Rx-10045) are currently under clinical 
trials for the relief of chronic dry eyes.31 The aim of our 
study was to clarify the effect of RvE1 on osteoclasto-
genesis and determine its feasibility in the development 
of a new therapeutic approach to RA.
 We showed that RvE1 reduced the number of 
TRAP-positive osteoclast-like cells, which is consistent 
with a previous report indicating that RvE1 markedly 
decreased the number of differentiated osteoclasts in-
duced by macrophage colony-stimulating factor and 
RANKL in primary osteoclast cultures.16
 Recently, a new assay method of evaluating the 
bone resorption activity in RAW264.7 cells was reported 
based on the measurement of pit formation using calci-
um phosphate labeled with fluorescent polyanionic mole-
cules.25 With this method, we found that RvE1 decreased 
the bone resorption activity in RAW264.7 cells, in line 
with a previous report showing that RvE1 diminished 
dentin resorption in vitro.16 These results in RAW264.7 
cells suggest that RvE1 could inhibit RANKL-induced 
osteoclastogenesis and bone resorption.
 We further found that RvE1 significantly inhibited 
RANKL-induced NFATc1 and c-fos mRNA expres-
sion and the nuclear translocation of NFATc1 from the 
cytoplasm in RAW264.7 cells, providing a potential 
mechanism underlying this inhibitory effect of RvE1 on 
osteoclastogenesis. A previous study showed that RvE1 
attenuated the RANKL-induced nuclear translocation 
of the p50 subunit of NF-κB.16 Zhu and colleagues32 
reported another mechanism of RvE1 in osteoclasts in 
bone marrow cells of C57BL/6 mice, in which RvE1 
inhibits osteoclast fusion through binding NFATc1 to the 
pivotal fusion protein DC-STAMP, thereby suppressing 
RANKL-induced NFATc1 nuclear translocation. Anoth-
er report showed that Bioaggregate, a laboratory-synthe-
sized and calcium silicate-based nanoparticulate cement, 
also inhibited the translocation of NFATc1 and c-fos 
from the cytoplasm to the nucleus in osteoclast precursor 
cells, which was determined with immunofluorescence 
analysis.33
 Our data indicated that RvE1 inhibited RANKL-in-
duced osteoclastogenesis through suppressing the 
mRNA expression of NFATc1 and c-fos. NFATc1 is 
known as a master transcription factor that plays a 
key role in regulating the expression of several osteo-
clast-specific genes such as TRAP, cathepsin K and 
MMP-9, which are involved in regulating osteoclast 
differentiation.18 Our results suggested that RvE1 sig-
nificantly inhibited RANKL-induced cathepsin K and 
MMP-9 mRNA expression by decreasing the transloca-
tion of NFATc1 from the cytoplasm to the nucleus.
 We further showed that RvE1 might correct the im-
balance of RANKL and OPG expression in osteoblasts 
induced by IL-17 using MC3T3-E1 cells.
 PGE2 is well known to be the key mediator of in-
flammation, pain and joint destruction in RA, and its 
production is an important target of anti-inflammatory 
drugs. PGE2 is produced by the conversion of arachi-
donic acid to prostaglandin H2 by COX-1/COX-2, with 
the subsequent conversion of prostaglandin H2 to PGE2 
by mPGES-1, which is the terminal enzyme in the PGE2 
production process at the sites of inflammation, and has 
an important role in the pathogenesis of RA.34, 35 PGE2 
has several pro-inflammatory effects, including increas-
ing vascular permeability, vasodilation, blood flow and 
local pyrexia, along with potentiation of pain caused by 
other agents. Previous studies showed that PGE2 stim-
17
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ulates osteoclast differentiation through the prostanoid 
receptors EP4 and EP2 by inducing RANKL production 
and inhibiting OPG expression.36–38 OPG is a soluble de-
coy receptor for RANKL that prevents it from binding 
to RANK. RANKL interacts with its receptor, which 
is expressed on osteoclast precursors, to induce the 
differentiation and activation of osteoclasts.21 A recent 
study showed that EPA and DHA inhibit PGE2-induced 
RANKL expression in MC3T3-E1 cells.39 Similarly, we 
showed that RvE1 inhibits the IL-17-induced COX-2 and 
mPGES-1 mRNA expression followed by PGE2 produc-
tion in MC3T3-E1 cells. These results might indicate 
that RvE1 indirectly inhibits osteoclastogenesis by re-
ducing IL-17-induced COX-2 and mPGES-1 expression 
in osteoblasts, suggesting that RvE1, like EPA and DHA, 
has an anti-inflammatory effect in RA.
 We did not examine the effects of RvE1 on the ex-
pression of PGE2 receptors in osteoblasts, such as EP4 
receptor. However, recent reports showed that PGE2 en-
hanced osteoclast formation through EP4 receptor acti-
vation on osteoblasts.40, 41 In addition, the effects of RvE1 
on the leukotriene B4 receptor subtype 1 (BLT1) ex-
pressed on osteoclasts, identified as receptors for RvE1,42 
should be further investigated, as a previous study 
showed that BLT1 mediates the actions of RvE1 on os-
teoclasts.16 Although the major effect of PGE2 on bone 
resorption is generally considered to occur indirectly 
via upregulation of RANKL and inhibition of OPG ex-
pression in osteoblastic cells,43 further study is needed 
to determine whether the EP4 receptor and BLT1 are 
therapeutic targets of RvE1. The mechanisms of inflam-
mation in RA are complex. In RA, many pro-inflamma-
tory cytokines including TNF-α, IL-1β, IL-6, and IL-
17 increase RANKL expression, leading to an increased 
osteoclast differentiation and subsequent bone erosions. 
Several of these cytokines also act synergistically with 
RANKL in promoting osteoclast differentiation.44 Fur-
ther studies are needed to assess the anti-inflammatory 
effect of RvE1 in RA.
 In conclusion, our results suggest that RvE1 inhibits 
osteoclastogenesis and bone resorption by suppressing 
RANKL-induced osteoclast differentiation. The mecha-
nism of action was determined to occur by the downreg-
ulation of NFATc1 and c-fos in osteoclasts and suppres-
sion of IL-17-induced RANKL expression through the 
autocrine action of PGE2 in osteoblasts. These findings 
suggest the potential of RvE1 as a new therapeutic ap-
proach to RA, providing the foundation for further pre-
clinical and clinical investigations.
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